MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, KZR had $4,568K increase in cash & cash equivalents over the period. -$9,830K in free cash flow.

Cash Flow Overview

Change in Cash
$4,568K
Free Cash flow
-$9,830K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-11,227 -30,260
Depreciation and amortization
227 494
Stock-based compensation
2,136 5,200
Amortization of premiums and discounts on marketable securities
494 1,275
Amortization of debt discount and issuance costs and other non-cash interest
37 201
Impairment loss of right-of-use asset
0 0
Reclassification of currency translation loss
282 -
Gain on disposition of fixed assets
4 -
Prepaid expenses and other current assets
432 -1,390
Other assets
-674 -1,741
Accounts payable, accrued and other current liabilities
-426 -6,322
Operating lease assets and liabilities
603 1,154
Net cash used in operating activities
-9,830 -29,985
Purchases of property and equipment
0 8
Proceeds from sale of fixed assets
9 -
Purchases of marketable securities
14,297 28,334
Maturities of marketable securities
30,000 53,481
Net cash provided by investing activities
15,712 25,139
Repayment of loan principal
1,305 2,608
Proceeds from issuance of common stock under employee stock incentive plans
0 35
Net cash (used in) provided by financing activities
-1,305 -2,573
Effect of exchange rate changes on cash and cash equivalents
-9 37
Net decrease in cash and cash equivalents
4,568 -7,382
Cash and cash equivalents at beginning of period
41,749 -
Cash and cash equivalents at end of period
38,935 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Kezar Life Sciences, Inc. (KZR)

Kezar Life Sciences, Inc. (KZR)